Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.32 |
| ▸ | DRD2 | P14416 | 5/20 | 0.32 |
| ▸ | HTR2A | P28223 | 4/20 | 0.32 |
| ▸ | HTR2C | P28335 | 4/20 | 0.32 |
| ▸ | HTR2B | P41595 | 4/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.31 |
| ▸ | NOS1 | P29475 | 3/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7684155 | 0.79 | ADRA1A (0.47) | HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL6768862 | 0.75 | DRD2 (0.36) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6768864 | 0.75 | OPRK1 (0.32) | — | |
| SCHEMBL7677439 | 0.74 | LMNA (0.37) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6768901 | 0.74 | LMNA (0.37) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6765019 | 0.74 | HTR1A (0.41) | HTR1ADRD2 | |
| SCHEMBL6768907 | 0.74 | LMNA (0.37) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6199543 | 0.73 | HTR1A (0.36) | HTR1ADRD2CA2 | |
| SCHEMBL4341944 | 0.72 | HTR1A (0.33) | HTR1ADRD2CA2 | |
| SCHEMBL9507945 | 0.71 | CYP19A1 (0.43) | HTR1AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800641-B2 | FOR THERAPY OF SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER, BIPOLAR DISORDER, PARKINSON'S DISEASE, L-DOPA INDUCED PSYCHOSES OR DYSKINESIAS, TOURETTE'S SYNDROME, HYPERPROLACTINEMIA, OR ADDICTION TO ETHANOL, NICOTINE, COCAINE | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20020183331-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-2,3-diaza-cyclopenta[a]naphthalene | WYETH | 2002-12-05 | — | — | US | disclosed |
| WO-2002088133-A1 | ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-6,9-DIOXA-2,3-DIAZA-CYCLOPENTA[a]NAPHTHALENE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183331-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-2,3-diaza-cyclopenta[a]naphthalene | SNCA, SYNJ1, SLC6A3 | HTR1A 86/4885DRD2 13/4885HTR2A 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.